Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Stem Cells. 2020 Dec 31;39(3):358–370. doi: 10.1002/stem.3320

Figure 4. Characterization of Treg, MSC and Treg+MSC combination therapy potency using activated rat microglia in vitro.

Figure 4.

(A): Assessment of multiple chemokines/cytokine production (LEGENDplex) by activated rat microglia. (B-C): Flow cytometry characterization of changes in microglia activation. (B): Changes in microglia cell surface marker expression after injury and treatment. (C): Representation histogram overlays of antibody expression in the injured control and Treg+MSC-18 combination therapy groups. All samples run in triplicate. Statistical significance between naive/treatment and activated control is indicated with (#) for p ≤ 0.05, (##) for p ≤ 0.01, (###) for p ≤ 0.001. Statistical significance between treatment groups is indicated with (*) for p ≤ 0.05, (**) for p ≤ 0.01, (***) for p ≤ 0.001. Treg, regulatory T cell; MSC, mesenchymal stromal cell; ELISA, enzyme-linked immunosorbent assay.